DSG Global, Inc. Subsidiary Imperium Motors’ EV Bus and Motor Home Division Introduces Exclusive Availability of Skywell K-15 Box Truck to North American Market

Skywell K-15 to be the First of Multiple Skywell EV Products Exclusively Marketed in North America Through Imperium Motors

SURREY, British Columbia, Jan. 05, 2021 (GLOBE NEWSWIRE) — DSG Global, Inc. (OTCQB: DSGT) (“DSGT” or the “Company”) via its subsidiary Imperium Motors’ EV Bus and Motor Home division announces the exclusive North American availability of Skywell’s K-15 electric box truck.

Featuring an all-electric drive train and the flexibility to be built out as a box truck, flatbed or stake bed body EV, Skywell’s K-15 competes in the low cab forward truck market as an environmentally responsible alternative to diesel or gasoline vehicles. The K-15 boasts an NEDC estimated mileage range of up to 250 miles per charge, offers DC fast charging and an attractive standard feature package.

“Pricing, quality, safety, and economics makes Imperium’s new K-15 offering one of the best vehicles in its class,” said William Rex, president of Imperium’s Bus and Commercial Division. “The high demand for commercial electric vehicles in 2021 has already begun and we believe this Skywell model leads the way in overall value in the commercial EV market.”

Skywell offers a wide range of EVs, including SUVs, city buses, coaches, passenger and cargo vans, truck and municipal vehicles, many of which will be exclusively offered via Imperium Motors throughout North America.

“Our Skywell team looks forward to a long and fruitful relationship with Imperium Motor Corp,” added Mr. Thomas Zhu, manager, division export sales, Skywell New Energy Automotive Group.

About Imperium Motor Company

Imperium Motor Company is an EV sales and marketing company that offers a wide variety of affordable vehicles equipped for the North American market with emphasis on great design, a green mindset, performance, and functionality. Vehicles will include high speed, mid-speed, and low speed electric vehicles including cars, trucks, SUVs, vans, buses and scooters. For additional information about Imperium Motors’ product lines, please visit www.imperiummotorcompany.com.

About VANTAGE TAG SYSTEMS INC (VTS)

Vantage Tag Systems provides patented electronic tracking systems and fleet management solutions to golf courses and other avenues that allow for remote management of the course’s fleet of golf carts, turf equipment and utility vehicles. Its clients use VTS’s unique technology to significantly reduce operational costs, improve the efficiency plus profitability of their fleet operations, increase safety, and enhance customer satisfaction. VTS has grown to become a leader in the category of Fleet Management in the golf industry, with their technology installed in over vehicles worldwide. VTS is now branching into several new streams of revenue, through programmatic advertising, licensing and distribution, as well as expanding into Commercial Fleet Management, PACER single rider golf carts, and Agricultural applications. Additional information is available at http://vantage-tag.com/

Safe Harbor for Forward-Looking Statements

Forward-looking statements in this press release include statements relating to, among other things, the Company’s ability to open its new customer facility and its ability to close and deliver on various purchase orders from customers, and the Company’s expansion into markets outside of the golf industry. Forward-looking statements are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: the timing and nature of any capital raising transactions; our ability to offer products and services for use by customers in new markets outside of the golf industry; our ability to deliver in a timely fashion and to our customers’ satisfaction the products purchased; the risk of competition; our ability to find, recruit and retain personnel with knowledge and experience in selling products and services in existing and new markets; our ability to manage growth; and general market, economic and business conditions. Additional factors that could cause actual results to differ materially from those anticipated by our forward-looking statements are under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year 2018 and our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all filed with the Securities and Exchange Commission. Forward-looking statements are made as of the date of this release, and we expressly disclaim any obligation or undertaking to update forward-looking statements.

Contacts:

Scott Arnold Chesapeake Group Media:
Managing Director +1-410-825-3930 Jules Abraham
CORE IR
[email protected]
CORE IR
516 222 2560  
[email protected]

Attachment



Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 12:40 p.m. Pacific Time.

A live audio webcast of the presentation will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company’s website for approximately 30 days.

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended September 30, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:

Christine Cassiano
Chief Communications Officer
(714) 552-0326
[email protected]



Noodles & Company to Participate in Two Investor Conferences in January

BROOMFIELD, Colo., Jan. 05, 2021 (GLOBE NEWSWIRE) — Noodles & Company (NASDAQ: NDLS) today announced that the Company will participate in two investor conferences in January.

On Monday, January 11, 2021, the Company will participate in a virtual fireside chat discussion at the 23rd Annual ICR Conference. Noodles’ discussion will begin at 12:30 PM ET and will be webcast live and archived on the Noodles & Company website. To access the webcast, please visit www.noodles.com under the “Investor Relations” tab, or directly through the ICR Conference website at www.icrconference.com.

The Company will also participate in the virtual Jefferies 10th Annual Winter Restaurant, Foodservice, Gaming, Lodging & Leisure Summit which will be held on January 19 – 20, 2021.

About Noodles & Company

Since 1995, Noodles & Company has been serving noodles your way, from noodles and flavors that you know and love, to new ones you’re about to discover for the first time. From indulgent Wisconsin Mac & Cheese to good-for-you Zoodles, Noodles serves a world of flavor in every bowl. Made up of more than 450 restaurants and 8,000 passionate team members, Noodles is dedicated to nourishing and inspiring every guest who walks through the door. To learn more or find the location nearest you, visit www.noodles.com.

Contacts:

Investor Relations

[email protected]

Media

Danielle Moore
(720) 214-1971
[email protected]

Source: Noodles & Company 



Gaming and Leisure Properties, Inc. Promotes Matthew Demchyk to Chief Investment Officer

WYOMISSING, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (“GLPI” or the “Company”) (NASDAQ: GLPI) announced today that Matthew Demchyk has been named Chief Investment Officer. Mr. Demchyk’s new role is effective immediately and he will report directly to GLPI Chairman and Chief Executive Officer, Peter Carlino.

Mr. Demchyk joined GLPI in February 2019 and most recently served as Senior Vice President of Investments.

Peter Carlino stated, “Matthew is a talented executive with a deep understanding of the public REIT space and the capital markets. Since joining GLPI, he has distinguished himself as a creative strategic thinker, thoughtful steward of our balance sheet, and prudent allocator of capital. His differentiated background and ability to work constructively with our executive team has proven invaluable during these unprecedented times, as evidenced by the instrumental role he has played in conceptualizing and structuring the innovative Tropicana transaction with Penn National. In the Chief Investment Officer role, Matthew’s unique skillset and unwavering focus on long-term value creation will greatly benefit GLPI’s shareholders.”

As Chief Investment Officer, Mr. Demchyk will lead GLPI’s investment strategy and be responsible for capital allocation, the evaluation of opportunities outside of the gaming sector, and the development of strategic relationships. Prior to joining GLPI, Mr. Demchyk was with Millennium Partners, where he served as Portfolio Manager of Real Estate Securities for over 9 years. Before Millennium, he oversaw a REIT investment strategy at Carlson Capital. He began his career at CenterSquare Investment Management, a leading REIT-dedicated asset manager, where he helped lead the team as Assistant Portfolio Manager.

Matthew graduated summa cum laude with a Bachelor of Science degree in Business Administration and a concentration in honors studies from Villanova University, where he majored in Finance. He is also a CFA Charterholder.

About Gaming and Leisure Properties

GLPI is engaged in the business of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements, pursuant to which the tenant is responsible for all facility maintenance, insurance required in connection with the leased properties and the business conducted on the leased properties, taxes levied on or with respect to the leased properties and all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties. GLPI elected to be taxed as a real estate investment trust (“REIT”) for U.S. federal income tax purposes commencing with the 2014 taxable year and was the first gaming-focused REIT in North America.

Contact  
Gaming and Leisure Properties, Inc. Investor Relations
Matthew Demchyk, Chief Investment Officer Joseph Jaffoni, Richard Land, James Leahy at JCIR
610/378-8232 212/835-8500
  [email protected]



Whole Earth Brands, Inc. to Present at the 23rd Annual ICR Virtual Conference

CHICAGO, Jan. 05, 2021 (GLOBE NEWSWIRE) — Whole Earth Brands, Inc. (the “Company”) (Nasdaq: FREE), today announced that Chief Executive Officer Albert Manzone and Chief Financial Officer Andy Rusie will present at the 23rd Annual ICR Virtual Conference, Inc. on Tuesday, January 12, 2021 at 8:30 AM ET.

The live audio webcast along with the accompanying presentation will be accessible in the News & Events section on the Company’s Investor Relations website at investor.wholeearthbrands.com. An archived replay of the webcast will also be available shortly after the live event has concluded.

About Whole Earth Brands

Whole Earth Brands is a global food company enabling healthier lifestyles and providing access to premium plant-based sweeteners, flavor enhancers and other foods through our diverse portfolio of trusted brands and delicious products, including Whole Earth Sweetener®, Swerve®, Pure Via®, Equal® and Canderel®. With food playing a central role in people’s health and wellness, Whole Earth Brands’ innovative product pipeline addresses the growing consumer demand for more dietary options, baking ingredients and taste profiles. Our world-class global distribution network is the largest provider of plant-based sweeteners in more than 100 countries with a vision to expand our portfolio to responsibly meet local preferences. We are committed to helping people enjoy life’s everyday moments and the celebrations that bring us together. For more information on how we “Open a World of Goodness®,” please visit www.WholeEarthBrands.com.

Contacts:

Investor Relations Contact:

Whole Earth Brands
312-840-5001
[email protected]

ICR
Jeff Sonnek
646-277-1263
[email protected]

Media Relations Contact:

Wyecomm
Penny Kozakos
202-390-4409
[email protected]



Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time.

A live webcast of the presentation will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences 

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX™ for adult patients with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:

Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
[email protected]

Media Contact:

Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
[email protected]



Artelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference

LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

A webcast of Artelo’s presentation will be available on-demand as of 6:00 a.m. EDT, Monday, January 11, 2021 and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of Artelo’s website at https://ir.artelobio.com/.

About Artelo Biosciences

Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Investor Relations Contact:

Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected]



PlantX Launches Baby Products Vertical with Else Nutrition

PlantX joins estimated USD $12.1 billion North American baby formula and toddler formula industry(1)

VANCOUVER, British Columbia , Jan. 05, 2021 (GLOBE NEWSWIRE) — via InvestorWire — PlantX Life Inc. (the “Company” or “PlantX”) (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce that the Company’s U.S. ecommerce platform www.PlantX.com will begin featuring baby formula products from Else Nutrition Holdings Inc. (“Else Nutrition”) (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL).

The addition of plant-based baby formula allows PlantX to further expand its category verticals. Else Nutrition’s baby formula will be the first product available to order in the new baby products section of the Company’s U.S. ecommerce platform, https://plantx.com/brand/else-nutrition/.

“We are thrilled to be listed on the PlantX platform. Joining this innovative online platform solely dedicated to plant-based companies aligns perfectly with our mission to bring clean label and sustainable plant-based options for parents to nourish their infants,” said Hamutal Yitzhak, CEO and co-founder of Else Nutrition. “We are proud to be part of a platform of like-minded, purpose-driven brands and raising awareness for plant-based nutrition and its benefits to a growing segment of consumers. This will help bolster Else Nutrition’s presence in both North America and Europe.”  

The North America baby food and infant formula market continues to grow as new products are introduced, such as those announced by Else Nutrition and PlantX. According to IMARC Group, the market is expected to reach a value of US$16.6 billion by 2025 at a compound annual growth rate of 5.5% over the next five years.

Else Nutrition was founded to better serve children with allergies, intolerances and dietary restrictions as well as families who seek plant-based clean nutrition for their babies and toddlers. The plant-based baby formula contains natural and organic ingredients to create a sustainable upbringing for children that is free from dairy, GMOs, corn syrup and gluten. Intended for babies 12 months and older, the formula is made with primarily almonds, buckwheat and tapioca in addition to 20 vitamins and minerals to support growth and development at an early age.

“Launching the new baby products section of PlantX.com with Else Nutrition is very exciting for us,” said Julia Frank, PlantX CEO. “We’ve seen the success of the baby formula market, and having it in our plant-based umbrella only adds to the potential in this space.”

PlantX continues to advance its plans to open its first brick and mortar locations in San Diego, California, Squamish, British Columbia and Tel Aviv, Israel, with plans of future franchising and expansion across the globe. PlantX will also continue to expand its e-commerce capabilities around the world with new and exciting partnerships, acquisitions and verticals in the plant-based industry. As a partner of PlantX, Else Nutrition will be able to expand its distribution through the Company’s online distribution and future physical locations.

PlantX will be streaming its weekly live vodcast with PlantX founder Sean Dollinger interviewing Else Nutrition CEO, Hamutal Yitzhak. Ms Yitzhak will discuss the Else Nutrition partnership and the importance of plant-based nutrition. Watch the stream Saturday, Jan. 9, at 10:30 a.m. PST / 1:30 p.m. EST from the Company’s YouTube channel available at https://youtu.be/penSyIP2j14.

_________________________
[1] https://www.imarcgroup.com/north-america-baby-food-infant-formula-market

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant-based. With its fast growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing, and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs, and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle, and thriving in a longer, healthier, and happier life.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. Else Toddler Nutrition was a #1 Best Seller on Amazon in the Baby/Toddler Formula Category in 2020. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Children’s Hospital of Colorado, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

CONTACT INFORMATION

For additional information, please contact:

Alexandra Hoffman
Chief Marketing Officer
(323) 536-7973 
[email protected]

The Company website is http://investor.PlantX.com/.

Forward Looking-Information

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may,” “will,” “expect,” “likely,” “should,” “would,” “plan,” “anticipate,” “intend,” “potential,” “proposed,” “estimate,” “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, the Company’s ability to establish further verticals and partnerships, the benefits of Else Nutrition products, the trends and dietary habits of consumers, the efficacy of certain vitamins and minerals, the expected market size and growth of the baby food and formula market, the expansion of the Company’s e-commerce capabilities, the opening of the Company’s new brick and mortar locations in San Diego, CA, Squamish, B.C. and Tel Aviv, Israel and the business and strategic plans of the Company.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; a limited operating history, the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Additional risk factors can also be found in the Company’s continuous disclosure documents which have been filed on SEDAR and can be accessed at


www.sedar.com


. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Wire Service Contact

InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
[email protected]



PSYC Announces Formation of Advisory Board

Company welcomes three leading voices from the medical, science, and psychotherapeutic sectors

LAS VEGAS, NV, Jan. 05, 2021 (GLOBE NEWSWIRE) — Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a digital media leader within the emerging sector of medicinal psychedelics, is pleased to announce the formation of the Company’s Advisory Board. Joining its newly established board is George Y. Salameh, MD, Hyder A. Khoja, PhD, and Kelli Foulkroud, MS, LPA, LPC, RYT. And as PSYC moves ahead with its growth within the emerging sectors of medicinal psychedelics and digital mental health, these advisors bring tremendous value to the Company through their collective knowledge and expertise.

“We are incredibly grateful and privileged to have the opportunity to welcome such a diverse and highly-skilled group of experts to our Advisory Board,” said David Flores, Chief Executive Officer of Global Trac Solutions, Inc. “As we move ahead into our next phase of growth, I recognize how important it is to surround our team with experts who have the ability to bring a perspective that is uniquely and beneficially derived from their many years of professional and personal experience. It is also quite encouraging that each of these experts share the passion we have here at PSYC for not only building a very successful business over the next several years but utilizing it to contribute to the betterment of humanity through a collective development and deployment of tools and resources intended to improve and optimize mental health and wellbeing.”

Dr. Salameh brings more than 35 years of experience within the medical community where he has served in the sectors of family and emergency practice and has held his California State Medical License since 1987. In addition to his extensive knowledge and experience as a physician, Dr. Salameh has also achieved success as an entrepreneur and as a real estate developer. He has also provided strategic consulting services for startup biotech and medical product companies in collaboration with San Diego venture capitalists for the past ten years.

Dr. Khoja has over 19 years of experience in the fields of molecular biology and genetic engineering and is an expert in translating ideas into action, including innovation, commercialization, and knowledge mobilization. His expertise in science and policy domains has led to a distinguished career in scientific research and business development with a passion for Molecular Biology and Genetic Engineering. Dr. Khoja leverages his knowledge in drug discoveries from plant extracts and analytics to validate consistent medical-grade plant nano-molecules for therapeutics. Dr. Khoja received his doctorate (Ph.D.), in 2003 with honors in Molecular Biology and Genetic Engineering from a French Ivy league: INP-ENSAT and had his Post-doctoral training from the Michigan State University a US land grant university. 

Kelli Foulkrod, MS, LPA, LPC, RYT has worked in the mental health field for over 19 years in a variety of academic and clinical settings. She is a transpersonal psychotherapist, trauma-informed yoga teacher, ceremonialist, and psychedelic integration therapist based in Austin, Texas, and is also licensed in Colorado. For the past ten years, she has managed her private practice, the Organic Mental Health Center, where she has focused her expertise and energy in supporting healing in trauma and complex PTSD, pregnant and postpartum women and their families, reproductive trauma, grief and loss, psychosis, bipolar, OCD, and treatment resistant depression.

Over the coming months, it is the Company’s intent to strategically add additional experts to its Advisory Board whom it believes may contribute to its continued growth and emergence as a leader within the sectors of medicinal psychedelics and digital mental health.

About Global Trac Solutions, Inc. (OTCPink: PSYC)

At Global Trac Solutions we are integrating media, creativity, and technology to develop and deploy thought-provoing ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters.

PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis. PSYC is your source for current investment related news specific to psychedelic medicines and cutting-edge research improving overall health, moving this sector into the mainstream.

We believe in a forward-thinking approach that embraces groundbreaking new technology and innovations and through the vision of business development we intend to continue to evolve into these unchartered territories as the industry leaders of the future. We truly are the right TRAC to follow.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors, including the effect of COVID-19, that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are disclosed on the OTC Markets.com website.

Disclaimer: Global Trac Solutions, Inc. does not in any way encourage or condone the use, purchase, sale or transfer of any illegal substances, nor do we encourage or condone partaking in any unlawful activities. We support a harm reduction approach for the purpose of education and promoting individual and public safety. If you are choosing to use psychedelic substances, please do so responsibly.

Corporate Contact:

Global Trac Solutions, Inc. (PSYC)
www.globaltracsolutions.com
(702) 239-1919
[email protected]
OTCPINK: PSYC



Workday Co-Founder and Co-CEO Aneel Bhusri to Present Virtually at the Goldman Sachs Technology and Internet Conference 2021

PLEASANTON, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Workday, Inc. (NASDAQ: WDAY), a leader in enterprise cloud applications for finance and human resources, today announced that Aneel Bhusri, co-founder and co-CEO of Workday, will present at the Goldman Sachs Technology and Internet Conference 2021 on Tuesday, Jan. 12, at 9:10 a.m. Pacific Time / 12:10 p.m. Eastern Time. Individuals may access the live webcast of the presentation here.

A replay of the presentation will be available on the Workday Investor Relations site for a minimum of 30 days after the conference takes place.

About Workday


Workday
 is a leading provider of enterprise cloud applications for finance and human resources, helping customers adapt and thrive in a changing world. Workday applications for financial management, human resources, planning, spend management, and analytics have been adopted by thousands of organizations around the world and across industries – from medium-sized businesses to more than 45 percent of the Fortune 500. For more information about Workday, visit workday.com.

© 2021. Workday, Inc. All rights reserved. Workday and the Workday logo are registered trademarks of Workday, Inc. All other brand and product names are trademarks or registered trademarks of their respective holders.

Investor Relations Contact:

Justin Furby
[email protected]

Media Contact: 

Nina Oestlien
[email protected]